Atypical Antipsychotics: Life-Cycle Management and Future Trends

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Overview of Antipsychotics Marketplace
• Key Players- Atypical Antipsychotics
  • Johnson & Johnson' s Risperdal
  • Eli Lilly' s Zyprexa
  • AstraZeneca' s Seroquel
  • Pfizer' s Geodon
  • Bristol-Myers Squibb' s and Otsuka' s Abilify
• Life-Cycle Management of Atypical Antipsychotics
• Competition from New Therapies: How Will Currently Marketed Atypicals Fare?
  • Johnson & Johnson' s Paliperidone
  • Organon' s Asenapine
  • Solvay/Wyeth/Lundbeck' s Bifeprunox
  • Marketed Atypicals vs
• Market Outlook for Atypical Antipsychotics Through 2015

• 1. Currently Marketed Atypical Antipsychotics
• 2. Market Shares of Antipsychotics, 2000-2005
• 3. Key Patent Expiries in the Antipsychotics Marketplace
• 4. Comparison of Atypical Antipsychotics on Various Parameters
• 5. First and Second Most-Preferred Atypical Antipsychotics, by Indication and Region, 2005
• 6. Marketed Atypical Antipsychotics: New Formulations and Nonapproved Indications Under Clinical Investigation
• 7. Promising "New-Generation" Atypical Antipsychotics

• 1. Atypical Antipsychotics, Sales Growth, 2000-2005
• 2. Projected Market Share of Current Leading Atypicals vs 2010-2015
• 3. Projected Regional Antipsychotics Sales, 2010 and 2015